OVERVIEW
In this live, virtual event a panel of experts in prostate cancer discuss the practical considerations of oral therapies and common adverse events associated with approved agents for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). Our experts will provide clinical guidance, explaining the most appropriate steps for patient care based on available clinical trial data on current and emerging treatment options, clinical practice guidelines, and their clinical experience regarding the use of androgen deprivation therapy, chemotherapy, and second-generation antiandrogens. Most importantly, you will hear from a patient who will discuss tactics by which patients can be empowered to have discussions with their oncologists to incorporate second-generation antiandrogen therapies into their treatment course.
GOAL STATEMENT
The goal of this activity is that learners will be better able to incorporate the latest data into the management of patients with mHSPC.
LEARNING OBJECTIVES
Upon completion of this activity, participants will: Have increased knowledge regarding the [LIST] [ITEM]Clinical data for mHSPC regimens that include androgen deprivation therapy (ADT), chemotherapy, and second-generation antiandrogens [ITEM]Strategies to incorporate ADT, chemotherapy, and second-generation antiandrogens for the treatment of patients with mHSPC [/LIST] Have greater competence related to [LIST] [ITEM]Selecting the appropriate therapy for patients with mHSPC [/LIST] Demonstrate greater confidence in their ability to [LIST] [ITEM]Incorporate regimens with ADT, chemotherapy, and second-generation antiandrogens for patients with mHSPC [/LIST]
ACCREDITATION STATEMENT
[JALOGO] [MEDSCAPE] In support of improving patient care, Medscape LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. [ICPE] This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credit for learning and change.
[bold]For Physicians [/bold] Medscape, LLC designates this live activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. [bold]For Nurses [/bold] Awarded 0.50 contact hour(s) of nursing continuing professional development for RNs and APNs.
Supported by an independent educational grant from [bold]Bayer[/bold].
Developed through a partnership between Medscape and ZERO – The End of Prostate Cancer.